Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO

Executive Summary

Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.

You may also be interested in...



Lilly Puts Down $200m To Use Dicerna's RNAi Platform For Metabolic, Neurological Diseases

Dicerna CEO tells Scrip the companies talked for two years and the collaboration came together as new Lilly R&D leadership looked to add novel approaches. Milestone fees of $350m per target for 10 or more targets value the deal at $3.7bn.

Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth

Lilly’s new CEO David Ricks said he had confidence in the Trump Administration’s ability to understand and respond to the biopharma industry’s needs as well as address drug pricing concerns. The company’s fourth quarter earnings could insulate it from cost criticism, since sales volume drove revenue gains, not prices.

Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines

Shaw is the former US President of rival Novartis and a rising figure in big pharma. She will take over the role previously held by Ricks, who became CEO Jan. 1. Conterno will assume President USA role.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel